lead optimization

(redirected from Drug development)
Also found in: Wikipedia.

lead optimization

(lēd)
The synthetic refinement of a candidate drug from its crude or original state into an agent that is safer, more useful, or more marketable.
References in periodicals archive ?
Smooth Drug Development announced gaining the internationally renowned ISO 9001:2008 certification .
The underlying principle of the platform is to enable the identification of compounds with the most optimal safety or bioavailability profiles as early in the drug development process as possible.
It is now apparent that one major application of toxicogenomics in drug development is the identification and characterization of early predictive biomarkers of toxicity.
Go inside the drug development and FDA regulatory process with today's most authoritative and popular reference on the topic.
Pathways to Efficient Drug Development - Advances in Modeling and Simulation Outcomes to Fuel Pipeline Productivity
Australian pharmaceutical manufacturing and drug development company, Institute of Drug Technology Australia Limited (ASX: IDT) has entered into an agreement to acquire from Mayne the business of CMAX Pty Ltd, an Adelaide-based clinical trials research unit.
Extended Service Offering Creates Solid Drug Development Foundation, Allowing Customers To "Get it Right the First Time"
NASDAQ: CRIS), a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, announced today that Genentech, a collaborator, has treated the first patient in a Phase I clinical trial of a systemically administered small molecule Hedgehog antagonist for testing in advanced cancer.
Moebius has more than 16 years of strategic drug development experience in Europe, the United States and Japan and has personally overseen the development of NCEs in epilepsy, Parkinson's disease, depression, Alzheimer's disease and vascular dementia, ADHD, spasticity, neuropathic pain, chronic pain, and addiction.
com/reports/c47910) has announced the addition of Toxicity Biomarkers: Promising Tools for Accelerated Drug Development to their offering.
CAC), an international contract research organization specializing in oncology drug development and medical consulting.
SSCI's CEO, Sally Byrn, who was named Vice President, Physical and Analytical Chemistry at Aptuit, stated "Together SSCI and Aptuit are in a great position to reengineer the drug development process, bringing our customers unprecedented speed to market while helping to achieve the FDA mandate of Quality by Design.
Full browser ?